MRS. KIMBERLY D FORNISS O.D.
Prescription History 1720036668
Optometrist in Indianapolis, IN

NPI Status: Active since May 04, 2006

Contact Information

5525 GEORGETOWN RD
SUITE J
INDIANAPOLIS, IN
ZIP 46254
Phone: (317) 297-1788
Fax: (317) 297-1790

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MRS. KIMBERLY D FORNISS O.D., an active Optometrist specialist practicing in Indianapolis, IN. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 183 documented patient claims. Among these therapy options, the most frequently utilized medication is Latanoprost, which accounts for 85 claims alone.

Medication Index

No matching medications currently found on file.

Azelastine Hcl

Generic Formulation: Azelastine HclSpecialty: Optometry
Provider Metrics Summary
Total Claims 17
30-Day Fills 21.0
Days Supply 612
IN State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills53.9
Peer Average Days Supply1,560
Conservative Utilization

This provider writes prescriptions for this formulation 50.0% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $663.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$39.01

State Avg Cost Per Claim

$50.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to relieve nasal symptoms such as runny/itching/stuffy nose, sneezing, and post-nasal drip caused by allergies or other conditions. Azelastine belongs to a class of drugs known as antihistamines. It works by blocking certain natural substances called histamines that are responsible for nasal symptoms.

Dorzolamide-Timolol

Generic Formulation: Dorzolamide Hcl/Timolol MaleatSpecialty: Optometry
Provider Metrics Summary
Total Claims 15
30-Day Fills 33.9
Days Supply 1,015
IN State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills144.5
Peer Average Days Supply4,317
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.3% less volume than the regional standard for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $331.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$22.09

State Avg Cost Per Claim

$32.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains two drugs used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (such as ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. Timolol belongs to a class of drugs known as beta-blockers, and dorzolamide belongs to a class of drugs known as carbonic anhydrase inhibitors.

Latanoprost

Generic Formulation: LatanoprostSpecialty: Optometry
Provider Metrics Summary
Total Claims 85
30-Day Fills 126.1
Days Supply 3,574
IN State Average Benchmarks
Peer Average Claims121.0
Peer Average 30-Day Fills234.6
Peer Average Days Supply6,777
Conservative Utilization

This provider writes prescriptions for this formulation 29.8% less frequently than the standard regional baseline metric for practitioners inside IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,277.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.03

State Avg Cost Per Claim

$23.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.

Therapeutic Applications

Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (such as ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid within the eye which results in lower pressure. Lowering high pressure inside the eye helps to prevent blindness.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Optometry
Provider Metrics Summary
Total Claims 66
30-Day Fills 66.0
Days Supply 1,217
IN State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply494
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 120.0% higher than the standard regional baseline profile for IN. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $988.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.97

State Avg Cost Per Claim

$13.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MRS. KIMBERLY D FORNISS O.D. provides transparency into local medical care patterns within Indianapolis, IN.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Optometrist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.